National Resource Center for Academic Detailing [NaRCAD]     857.307.3801
NaRCAD
  • About
    • Why We Matter
    • Our Team
    • Contact Us
  • Learning Center
    • The AD Archives
    • The AD Core Toolkit >
      • Opioid Safety Toolkit
      • HIV Prevention Toolkit
    • MATERIALS LIBRARY
  • News & Media
    • Blog
    • Podcast Series
    • E-Newsletter
  • Detailing Directory
    • Partners by Location
  • EVENTS SERIES
    • Training Series
    • CONFERENCE SERIES
    • THE CONFERENCE HUB
  • About
    • Why We Matter
    • Our Team
    • Contact Us
  • Learning Center
    • The AD Archives
    • The AD Core Toolkit >
      • Opioid Safety Toolkit
      • HIV Prevention Toolkit
    • MATERIALS LIBRARY
  • News & Media
    • Blog
    • Podcast Series
    • E-Newsletter
  • Detailing Directory
    • Partners by Location
  • EVENTS SERIES
    • Training Series
    • CONFERENCE SERIES
    • THE CONFERENCE HUB

The DETAILS BLOG

Capturing Stories from the Field: Reflections, Challenges, & Best Practices

Supporting Academic Detailing Programs After Pharmageddon

12/23/2014

8 Comments

 
Picture
by Jerry Avorn, M.D., NaRCAD Co-Director
A number of academic detailing programs began in the 1990s or early 2000s, when the cost of many useful medications in primary care was prohibitive. Some were available then only as expensive brand-name products: clopidogrel (Plavix) as an anti-platelet agent, alendronate (Fosamax) for osteoporosis.  Others could plausibly be replaced in some patients by similar agents in the same class: atorvastatin (Lipitor) for elevated cholesterol, celecoxib (Celebrex) for arthritis and pain, omeprazole and esomeprazole (Prilosec and Nexium) for acid-peptic disease. Then came the game-changing developments around 2011-2012, when the patents on blockbuster drugs like Lipitor and Plavix expired. This was referred to as the “patent cliff” by some; others dubbed it “Pharmageddon.”

Meanwhile, discount drug stores, led by Wal-Mart, had been introducing the $4-a-month generic prescription. Within a short period of time, most common drug categories had one or more key medications available that made it possible to manage many common primary care problems—hypertension, high cholesterol, diabetes—for a modest monthly cost.

While these developments were a boon to patients and payors, they were not good news for the large pharma companies, which had to reassess their business models in the post-blockbuster era. But Pharmageddon also had an impact on another, much smaller group: the tiny international academic detailing community.  Many sponsors of academic detailing programs had been attracted by the prospect that promoting evidence-based practice could also help contain rising drug costs. While that was never the main goal of such work for many of us, it was an attractive feature—at least in part—for many funders in both the public and private sectors.

Stark evidence of this came in a conversation I had with a health insurance executive about the possibility of starting an academic detailing program for primary care providers. “Frankly,” he told me, “we’re not focusing much attention any more on drugs in primary care. Many of them are pretty cheap now. All our energies are going to the expensive specialty drugs.”

I guess if the bottom line is all that matters, any M.B.A. would come to the same conclusion about academic detailing in primary care. However, if the mission of academic detailing is to help health care professionals take better care of their patients, then the goal of quality improvement serves as reason enough in itself. Several state government agencies get this (PA, SC, VT, MA, etc.), as do some Canadian provinces and other nations. But in many private U.S. health care systems, the bottom line still rules.

Luckily, things are changing yet again to make academic detailing potentially attractive even for those whose focus is mostly on finances. Growing impact of the HEDIS measures (Healthcare Effectiveness Data and Information Set) and the Medicare “stars” rating system means that millions of dollars of reimbursement now depend on how a health care system performs on several quality measures. Many of these measures depend upon optimal medication use for conditions such as diabetes, hypertension osteoporosis, and elevated cholesterol; others assess cancer screening and other non-medication-related priorities that can be addressed by academic detailers.

So for those of us who always felt that academic detailing is about optimizing patient care, that goal remains as important as ever. And for those who are concerned with how academic detailing can affect a health care system’s bottom line, even though Pharmageddon temporarily took the edge off some of those concerns in primary care, the renewed focus on outcomes and quality measures, many of which are so drug-dependent, means that this reason to improve prescribing is also now back on the table.

About the Author: Dr. Jerry Avorn is Professor of Medicine at Harvard Medical School and Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics. A general internist and geriatrician, he pioneered the concept of academic detailing and is recognized internationally as a leading expert on this topic and on optimal medication use, particularly in the elderly. Dr. Avorn has published over 250 papers on these topics over the past three decades.
This article originally appeared in NaRCAD’s Winter 2014/15 Newsletter.

8 Comments

    Highlighting Best Practices

    We highlight what's working in clinical education through interviews, features, event recaps, and guest blogs, offering clinical educators the chance to share successes and lessons learned from around the country & beyond.

    Search Archives
    by Topic:

    All
    21st Century Cures Act
    5 Year Anniversary
    80% By 2018 Campaign
    Academic Detailing
    Addiction
    ADHD
    Affordable Care Act
    AHRQ
    AIDS
    Alaska
    Alosa Health
    Alternative Facts
    American Academy Of Pediatrics
    American Cancer Society
    Annual Community Survey
    Antibiotics
    Apply To Present
    Arkansas
    Aspirin
    Atrius
    Autism
    Autism Screening
    Behavior Change
    Bell County Kentucky
    Best Practices
    Big Data
    Blood Pressure
    Boston
    Breast Cancer
    California
    Canada
    Cancer Roundtable
    Cancer Screening
    Cannabinoids
    Cannabis
    Cardiology
    Cardiovascular Health
    Care Delivery
    CDC
    Centers For Disease Control
    Cholesterol
    Chronic Disease
    Chronic Illness
    Chronic Pain
    Clinical Education
    Clinical Outreach Education
    Clinical Pharmacists
    Clinical Pharmacy
    Clinician
    Clinician Education
    Clinicians
    CME
    Coaching
    Collaboration
    Colorado
    Colorado ABCD
    Colorado Department Of Public Health And Environment
    Colorectal Cancer
    Communications Skills
    Community Based
    Community-based
    Compliance
    Conference
    Conference Series
    Connecticut
    Consultation
    COPD
    COrE Series
    Cost Savings
    Cultural Competency
    CVS Health
    Data
    Decision Making
    Denver
    Department Of Health
    Dependence
    Depression
    Detailing Aid
    Developmental Delays
    Diabetes
    Director's Letter
    Drug Approval
    Drug Costs
    Drug Regulation
    Drugs
    Drug Safety
    Early Childhood Development
    Education
    Educational Materials
    Efficacy
    Engagement
    Evaluating Evidence
    Evaluation
    Event
    Events
    Evidence
    Evidence-based
    Evidence Based Medicine
    Evidence-based Medicine
    Expert Insight Series
    Expert Panels
    Fall 2016 Training
    Fall 2017 Training
    FDA
    Florida
    Former Trainee
    Formularies
    Gaining Access
    Gatekeeper
    Geronotology
    Getting To Zero
    Guest Blog
    Healthcare
    Healthcare Improvement
    Healthcare Reform
    Health Care System
    Healthcare Transformation
    Health System
    Health Systems
    HealthTeamWorks
    Heart Disease
    Heart Failure
    HEDIS
    HepC
    HIV
    HPV
    Hypertension
    Idaho
    IDIS
    Incontinence
    Interactivity
    Interdisciplinary
    Interview
    Jerry Avorn
    Kaiser Permanente
    Kentucky
    Key Messages
    Keynote Speakers
    Kidney Disease
    LaNet
    LA Net
    Las Vegas
    Learning Center
    Letter
    Lifestyle Management
    Local Response
    Long-term Care
    LOOPR
    Los Angeles
    Lung Disease
    Mammography
    Manchester
    Massachusetts
    Massachusetts Department Of Health
    MAT
    Materials Development
    Medical Centers
    Medicare
    Medication
    Medication Assisted Treatment
    Medicine
    Mental Health
    Messaging
    Michigan
    Mississippi
    Morphine Milligram Equivalents
    NACCHO
    Naloxone
    #NaRCAD2014
    #NaRCAD2015
    #NaRCAD2016
    #NaRCAD2017
    #NaRCAD2018
    NaRCAD Training Alumni
    National AD Service
    Needs Assessment
    Networking
    Nevada
    New Hampshire
    New Mexico
    New York
    North Carolina
    NYDOHMH
    Obesity
    Ohio
    Oklahoma
    On The Road
    Opioid
    Opioid Crisis
    Opioids
    Opioid Stewardship
    Opioid Use Disorder
    Oregon
    Outreach
    Outreach Education
    Overdose
    Overdose Prevention
    Overprescribing
    Pain
    Pain Medication
    Pain Medicine
    Partner Network
    Patient Care
    Patients
    PCORI
    PDMP
    PDSA Cycle
    Pediatrics
    Pediatric Screening
    Pennsylvania
    Pertussis
    Pharma
    Pharmaceutial
    Pharmaceutical
    Pharmaceuticals
    Pharmacology
    Pharmacotherapy
    Pharmacy
    Pharmageddon
    Pilot Project
    Policy
    Polypharmacy
    Practice-centered
    Practice Facilitation
    Pregnancy
    Pregnancy-related Depression
    Prenatal Health
    PrEP
    Prescribers
    Prescribing
    Prescribing Guidelines
    Prescription Drug Management
    Prescriptions
    Prevention
    Primary Care
    Primary Care Burnout
    Prisoner Health
    Program Evaluation
    Program Management
    Project PrIDE
    Provider Education
    Providers
    PTSD
    Public Health
    Pulmonology
    Quality Improvement
    RAPID
    Readmission
    Referral
    Registration Open
    Research
    Research Study
    Resources
    Rhode Island
    Role Play
    Rural AD Programs
    Safe Prescribing Guidelines
    San Francisco
    San Francisco Department Of Public Health
    Save The Date
    Scaling Up
    Screening
    Serious Mental Illness
    Sexual Health
    SFDPH
    Smoking Cessation
    Social Marketing
    Social Marketing Skills
    Stakeholders
    Statins
    STDs
    Strategies
    Stroke
    Team Approach
    Technical Assistance
    Technology
    Tennessee
    Texas
    The New Yorker
    Tobacco-treatment
    Total Quality Management
    Training
    Training And Support
    Training Recap
    Training Series
    Transgender
    Transitional Care
    Treatment
    Trends
    VA
    Vaccination
    Vaccinations
    Vermont
    Veterans
    Veterans Affairs
    Veterans Health
    Virginia
    Washington D.C.
    Washington State
    West Virginia
    Workshop
    Zika Virus

    RSS Feed


​NaRCAD is a program of the Division of Pharmacoepidemiology & Pharmacoeconomics [DoPE], Department of Medicine at Brigham & Women's Hospital.
Proudly powered by Weebly